Celgene buy forcing reckoning among Bristol-Myers Squibb’s R&D partners
A lengthy R&D update for CytomX’s pipeline review day included a brief note on a housecleaning at Bristol-Myers Squibb that cost the smaller biotech a partner on 3 of their allied programs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.